The reliability of a breath‐hold protocol to determine cerebrovascular reactivity in adolescents by Koep, JL et al.
R E S E A R CH A R T I C L E
The reliability of a breath-hold protocol to determine
cerebrovascular reactivity in adolescents
Jodie L. Koep1,2 | Alan R. Barker1 | Rhys Banks1 | Rohit R. Banger1 |
Kate M. Sansum1 | Max E. Weston1,2 | Bert Bond1
1Children's Health and Exercise Research
Centre, Sport and Health Sciences, College of
Life and Environmental Sciences, University of
Exeter, Exeter, UK
2School of Human Movement and Nutrition
Sciences, University of Queensland, Saint
Lucia, Queensland, Australia
Correspondence
Bert Bond, Children's Health and Exercise
Research Centre, College of Life and
Environmental Sciences, University of Exeter,
Exeter, EX1 2LU, UK.
Email: b.bond@exeter.ac.uk
Abstract
Purpose: Cerebrovascular reactivity (CVR) is impaired in adolescents with cardiovas-
cular disease risk factors. A breath-hold test is a noninvasive method of assessing
CVR, yet there are no reliability data of this outcome in youth. This study aimed to
assess the reliability of a breath-hold protocol to measure CVR in adolescents.
Methods: Twenty-one 13 to 15 year old adolescents visited the laboratory on two
separate occasions, to assess the within-test, within-day and between-day reliability
of a breath-hold protocol, consisting of three breath-hold attempts. CVR was defined
as the relative increase from baseline in middle cerebral artery mean blood velocity
following a maximal breath-hold of up to 30 seconds, quantified via transcranial
Doppler ultrasonography.
Results: Mean breath-hold duration and CVR were never significantly correlated
(r < .31, P > .08). The within-test coefficient of variation for CVR was 15.2%, with no
significant differences across breath-holds (P = .88), so the three breath-hold
attempts were averaged for subsequent analyses. The within- and between-day coef-
ficients of variation for CVR were 10.8% and 15.3%, respectively.
Conclusions: CVR assessed via a three breath-hold protocol can be reliably measured
in adolescents, yielding similar within- and between-day reliability. Analyses revealed
that breath-hold length and CVR were unrelated, indicating the commonly reported
normalization of CVR to breath-hold duration (breath-hold index) may be unneces-
sary in youth.
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1 | INTRODUCTION
Cerebrovascular reactivity (CVR) refers to the ability of the human
brain to modulate cerebral blood flow in response to changes in stim-
uli, such as the partial pressure of arterial carbon dioxide (PaCO2).
Impairments in CVR are an important hallmark for cerebrovascular dis-
ease (CVD) progression. Research highlights that impairments in CVR
in adults is associated with Alzheimer's disease,1 neurocognitive
decline,2 stroke,3,4 and independently predicts future CVD events in
patients with CVD risk factors.5 Impairments in CVR are present in
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youth with CVD risk factors, such as hypertension6,7 and white coat
hypertension,8 supporting its sensitivity to CVD risk factor status in
this population. Consequently, there is a growing interest in the non-
invasive measurement of CVR in pediatric populations.9
Transcranial Doppler ultrasonography can be used to determine
the reactivity of middle cerebral artery blood velocity (MCAv) to a
hypercapnic stimulus, such as CO2 breathing.
10 A breath-hold stimulus
might provide a more convenient alternative to CO2 breathing, as it is
easier to administer, has minimal associated cost, and may be less
intimidating, which may be of particular value when working with
pediatric groups. During a breath-hold test, changes in PaCO2
(reflected as end-tidal CO2, PETCO2) account for approximately two-
thirds of the CVR response, with one quarter attributed to changes in
mean arterial pressure (MAP).11 Furthermore, CVR determined from
transcranial Doppler ultrasonography using a breath-hold test is signif-
icantly positively correlated (r = .67) with CO2 breathing induced CVR
in adults presenting symptoms for cerebrovascular disease.12 Given
data support the breath-hold as an appropriate surrogate measure of
CO2 breathing tests, a breath-hold stimulus has merit in pediatric
groups, when CO2 breathing might not be feasible. However, despite
the continued use of the breath-hold test in the literature,8,13,14 the
within- and between-day reliability of this approach in a pediatric
population is unknown. Additionally, a precise methodological
approach needs to be made clear, as current breath-hold protocols
differ between existing adult studies.
Breath-hold induced CVR is commonly quantified using the
breath-hold index (BHI), or the percentage increase in MCAv divided
by breath-hold length.12,15 The BHI has been reported to have appro-
priate within-day reliability (60 minutes) in a study of healthy adults,
however its between-day reliability (24 hours) was poor.16,17 This
questions the appropriateness of the BHI as a measure of CVR for
studies involving multiple visits on separate days. Furthermore, no
studies have explored the relationship between breath-hold length
and the increase in MCAvmean, to determine the validity of normaliz-
ing increases in MCAvmean to breath-hold length.
Previous work has also failed to identify the most reliable method
of analysis of the MCAvmean response within a test protocol, with
some reporting CVR as a BHI15 and others as percentage change from
baseline (CVR%).7 In addition, the number of breath-holds performed
is not standardized and averaging methods are unclear, or not
reported.12,18 Importantly, evidence suggests that the breath-hold
response might only be sensitive to changes in cerebrovascular health
when performed multiple times within a single assessment.19 Finally,
many studies have failed to report the time when peak MCAvmean is
recorded following the breath-hold,11,12 while others record the per-
centage increase during the breath-hold.3 In order to determine how
best to analyze and report CVR, measures of within-test reliability are
needed. In addition, given that cerebral blood flow is sensitive to
changes in PaCO2, partial pressure of arterial oxygen (PaO2) and
MAP,11 the simultaneous measurement of these variables has merit in
determining the impact of a breath-hold challenge on these physiolog-
ical parameters, which may contribute to altered CVR.20
The purpose of this study was to identify the within-test, and
within- and between-day, reliability of a CVR breath-hold protocol in
an adolescent population, and to identify methodological and analyti-
cal approaches to improve the reliability of the breath-hold test to
determine CVR in youth.
2 | METHODS
2.1 | Participants
Twenty-one 13 to 15 year old adolescents volunteered to take part in
this study. Participant assent was obtained alongside written informed
parental consent prior to participation in the study, which was
approved by the institutional ethics committee (171206/B/07). Exclu-
sion criteria included any known cardiometabolic diseases, contraindi-
cations to exercise, or use of medication known to influence vascular
function. One participant was removed from analyses due to an inabil-
ity to regularly perform the breath-holds without a valsalva maneuver.
Participants were familiarized to all measures on a preliminary
visit. During this visit, body mass (Hampel XWM-150K, Hampel Elec-
tronics Co., Taiwan) and stature (Seca stadiometer SEC-225, Seca,
Hamburg, Germany) were recorded to the nearest 0.1 kg and 0.1 cm,
respectively, using standard procedures. Body mass index (BMI) cut-
off points were used to define lean, overweight and obesity status.21
Pubertal status was determined through self-assessment of secondary
sex characteristics according to the five stages of pubic hair
development.22
2.2 | Study protocol
Participants completed two experimental visits to the laboratory,
within a 3-week period. Participants were required to avoid vigorous
exercise for 24 hours prior to testing. Following a 12-hour overnight
fast, participants were transported to the laboratory for 8 AM and
rested in a darkened and temperature controlled room (24C) in the
supine position for 30 minutes prior to CVR assessment. To assess
within-day reliability, participants repeated these measures after
60 minutes, consuming only 300 mL of water and remained sedentary
in the laboratory.
2.3 | Assessment of cerebrovascular function
CVR was determined as the percentage increase in MCAvmean from
baseline to peak following each breath-hold attempt via transcranial
Doppler ultrasonography (Equation ((1))) (DWL, Doppler-BoxX,
Compumedics, Germany). Peak MCAv was defined as the highest
beat-to-beat MCAvmean following the breath hold. The time, mea-
sured in seconds, from exhalation to peak MCAvmean was defined as
time to peak.
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F IGURE 1 Beat-by-beat responses
of middle cerebral artery mean blood
velocity, A, and mean arterial pressure, B,
for a representative participant across
three breath-hold attempts
TABLE 1 Within-test reliability
Breath-hold Change in mean
P
Typical
error CV (%) rVariable 1 2 3 (1, 2) (2, 3)
Baseline MCAvmean (cm/s) 89.6 ± 14.9 86.9 ± 11.4 84.8 ± 12.5* −2.7 −2.1 .002 0.3 4.6 .92
Peak MCAvmean (cm/s) 130.5 ± 19.1 128.2 ± 17.6 124.5 ± 19.8* −2.3 −3.7 .003 0.3 3.2 .95
Recovery MCAvmean (cm/s) 82.7 ± 13.2 81.1 ± 12.2 80.4 ± 11.2 −1.6 −0.8 .14 0.3 3.9 .93
BH length (s) 25.5 ± 4.8 26.0 ± 4.4 25.0 ± 5.3 0.5 −1.9 .42 0.5 13.5 .73
Time to peak (s) 4.7 ± 2.6 4.2 ± 2.9 3.9 ± 2.9 −0.5 −0.3 .67 0.7 40.7 .43
CVR (%) 46.7 ± 12.0 47.5 ± 11.5 47.4 ± 14.5 0.8 −0.1 .88 0.5 15.2 .77
BHI (% s−1) 1.88 ± 0.48 1.85 ± 0.43 1.94 ± 0.60 −0.1 0.1 .62 0.6 16.2 .64
MAP baseline (mm Hg) 82 ± 14 82 ± 15 82 ± 15 −0.01 −0.02 .99 0.2 3.8 .97
MAP Δ during BH (mm Hg) 9 ± 9 10 ± 8 9 ± 9 1.2 −1.1 .53 0.5 119.7 .78
MAP peak (mm Hg) 97 ± 11 98 ± 11 99 ± 11 0.45 1.42 .46 0.4 4.4 .84
CVCi (cm/s mm Hg) 0.94 ± 0.2 1.10 ± 0.2 1.07 ± 0.2) 0.14 −0.03 .10 0.2 28.5 .91
Δ End-Tidal CO2 4 ± 3 4 ± 3 4 ± 3 −0.08 0.15 .95 0.5 22.4 .75
Stimulus index (CO2/O2) break point 0.43 ± 0.1 0.43 ± 0.1 0.42 ± 0.1 −0.01 −0.01 .48 0.4 8.1 .83
Note: Data presented as mean ± SD. P-values indicate ANOVA main effect, with significant effects highlighted in bold.
Abbreviations: ANOVA, analysis of variance; BH, breath-hold; BHI, breath-hold index; CO2, carbon dioxide; CV, coefficient of variation; CVR, cerebrovas-
cular reactivity; MAP, mean arterial pressure; MCAVmean, mean middle cerebral artery velocity; O2, oxygen.
*P < .05 compared to other breath-holds.





A 2-MHz probe was used to insonate the right MCA at an initial
depth of 50 mm. The Doppler signal was then acquired and secured
using an adjustable headset (DWL, DiaMon, Compumedics, Germany,
GmbH). Efforts were made to replicate the position of the probe and
depth of the scan, and on within- and between-day scans, the baseline
MCAvmean was recorded in an attempt to replicate the same position
and minimize any error. Beat-by-beat MCAvmean was calculated as the
mean across each cardiac cycle and exported for analysis. End-Tidal
CO2 (PETCO2) and End-Tidal O2 (PETO2) were measured throughout
the protocol, as a surrogate of PaCO2 and PaO2 (McSwain et al.
23).
Participants wore a leak-free facemask (Hans Rudolph, Shawnee, Kan-
sas) during the protocol to sample PETCO2 and PETO2 through a gas
analyzer (ADInstruments, Gas analyzer, ML206, Colorado Springs,
Colorado), which was calibrated via known concentrations of oxygen
and CO2. During the protocol, beat-by-beat blood pressure was non-
invasively measured by finger plethysmography (Finometer PRO,
Netherlands). All data were collected (Powerlab; model - 8/30,
ADInstruments) and stored at 200 Hz using an analogue-to-digital
converter interfaced with a laptop computer (Lab Chart version 8,
ADInstruments).
Baseline readings were averaged over 1 minute. Participants then
performed a maximal breath-hold for up to 30 seconds following a
normal inspiration while avoiding a valsalva maneuver, which was
coached on the preliminary visit. This protocol, consisting of a base-
line, breath-hold, and 1-minute recovery phase, was repeated three
times. Figure 1 shows representative MCAvmean and MAP responses
to this protocol.
2.4 | Data analyses
MAP was calculated from the raw blood pressure trace as one-third
systolic blood pressure + two-third diastolic blood pressure. The
change from baseline during the last 5 seconds of the breath-hold was
calculated, to determine the presence of a substantial increase in blood
pressure, defined as a valsalva maneuver. This increase was analyzed
visually by two researchers, and if MAP was substantially elevated
(>15 mm Hg) following the breath-hold, this breath-hold was removed.
Given that PETCO2 and PETO2 change simultaneously during the
breath-hold protocol, a stimulus index, defined as the ratio between
PETCO2 and PETO2 (PETCO2/PETO2) was calculated following previ-
ously used methods.24 This was calculated to quantify the magnitude
of the stimulus provided by the breath-hold assessment.
Data from the three breath-holds within a single assessment of
CVR were subsequently averaged and used to identify within-test
reproducibility, and how to reliably analyze CVR. This informed the
analysis of the within- and between-day CVR measures, in terms of
whether it is appropriate to take an average of the three breath-holds,
when the peak MCAvmean occurs, and whether reporting CVR as a
BHI is appropriate.
To explore changes in the ratio between MAP and MCAvmean, the
cerebrovascular conductance index (CVCi) was calculated as described
in Equation ((2)):
CVCi=MCAvmean=MAP ð2Þ
where MCAvmean and MAP are taken as the average during the base-
line preceding each breath-hold attempt.
2.5 | Statistical analyses
Statistical analyses were conducted using SPSS (version 25; IBM,
Armonk, New York) and data are presented as mean ± SD. Statistical
significance was accepted at an alpha of .05. Baseline and peak
MCAvmean, CVR, BHI, breath-hold duration, time to peak MCAvmean,
MAP, CVCi, and PETCO2 and PETO2 were analyzed using a mixed
model analysis of variance (ANOVA) with assessment (within-test and
F IGURE 2 Within-test correlation between breath-hold length, A,
cerebrovascular reactivity (CVR%), B, change in PETCO2 from baseline
to break point, and C, change in mean arterial pressure (MAP) from
baseline to break point
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within-day) or visit (between-day) as the main effects. For within-test
data, the relationship between mean breath-hold length and CVR was
explored using Pearson's correlation. Effect sizes for the ANOVA
model were displayed as partial eta squared (ηp
2), and interpreted as
<0.06 = small, 0.06 to 0.14 = moderate and >0.14 = large.25 For
within-test analyses where three breath-holds were analyzed, signifi-
cant difference between breath-hold attempts were located using
pairwise comparisons and interpreted using the P-value and standard-
ized effect sizes (d) to document the magnitude of the effect using the
following thresholds: ≥0.2 < 0.5 = small, <0.8 = moderate and
≥0.8 = large.25 The reproducibility of these outcomes was explored
using the typical error, expressed as a coefficient of variation (CV) and
intraclass correlation coefficient (r) for within-test, within-day, and
between-day analyses.26 Within-test outcomes of interest were also
analyzed for sex differences using an independent samples t test, with
effect sizes (d) calculated for these comparisons.
3 | RESULTS
Ten boys and ten girls were included in the study. The mean (SD) age
of the group was 14.3 (0.4) years, body mass: 55.1 (11) kg, stature:
154.5 (8.2) cm. Three participants were defined as overweight
according to BMI centile cut points.21 The maturity status was as fol-
lows: stage 2, n = 2 (one male); stage 3, n = 2 (one male); stage 4,
n = 14 (seven males); and stage 5, n = 2 (one male).
3.1 | Within-test reliability
The within-test reproducibility for parameters of interest is pres-
ented in Table 1. Baseline MCAVmean significantly declined across
the three breath-holds (ηp
2 = 0.29), with a significantly lower baseline
MCAVmean in breath-hold 3 than 1 (P = .001, d = 0.4) and 2
(P = .034, d = 0.2). Peak MCAVmean systematically declined across
the three breath-holds, with breath-hold 3 lower than 1 and 2
(P < .001, ηp
2 = 0.27; 1 vs 3: P = .003, d = 0.3, 2 vs 3: P = .02,
d = 0.2). Baseline PETO2 systematically increased across the three
breath-holds (np
2 = 0.24), with a significantly lower baseline PETO2 in
breath-hold 1 than 2 (P = .034, d = 0.3) and 3 (P = .006, d = 0.5). No
significant mean differences were apparent between breath-holds
for all other outcomes, including CVR and BHI (ηp
2 ≤ 0.19). Signifi-
cant intraclass correlations were observed between breath-holds for
all outcomes of CVR (.64 ≤ r ≤ .95) (P < .01), except time to peak
(r = .43, P = .67). Mean breath-hold duration was not significantly
correlated with CVR for breath-hold one (r = .31, P = .17); two
(r = .39, P = .08); or three (r = .35, P = .13), as shown in Figure 2A.
Mean breath-hold duration was not significantly correlated with the
change in PETCO2 from baseline to break point for breath-hold one
(r = .17, P = .44); two (r = .06, P = .79); or three (r = .17, P = .47), as
shown in Figure 2B. In addition, mean breath-hold duration was not
significantly correlated with the change in MAP for breath-hold one
(r = .30, P = .19); two (r = .32, P = .16); or three (r = .24, P = .31), as
shown in Figure 2C. The typical error expressed as a CV for all other
outcomes ranged from 2.0% (baseline PETCO2) to 119.7% (MAP Δ
during BH). The within-test outcomes informed the analysis of
breath-hold data for within- and between-day analysis, with it
deemed appropriate to take an average of the three breath-hold
attempts within the protocol. Within-test analyses also revealed that
there were no significant sex differences for baseline MCAvmean
(boys 84.1 ± 10.2 vs girls 90.3 ± 14.4 cm/s, P = .30, d = 0.5); peak
MCAvmean (boys 125.4 ± 17.7 vs girls 130.2 ± 19.8 cm/s, P = .56,
d = 0.3); and CVR (boys 48.9 ± 13.3 vs girls 45.3 ± 9.0%,
P = .48, d = 0.3).
TABLE 2 Within-day reliability
Variable Assessment 1 Assessment 2 Change in mean P value Typical error CV (%) r
Baseline MCAvmean (cm/s) 85.9 ± 11.9 82.9 ± 13.7 −2.9 .02 0.3 4.5 .92
Peak MCAvmean (cm/s) 126.8 ± 15.5 122.3 ± 21.0 −5.5 .02 0.4 5.8 .87
Recovery MCAvmean (cm/s) 81.0 ± 11.6 77.7 ± 13.6 −3.3 .03 0.4 5.7 .89
BH length (s) 25.2 ± 4.3 26.0 ± 4.2 0.8 .21 0.5 8.1 .81
CVR (%) 47.3 ± 11.7 46.2 ± 10.4 −1.1 .48 0.5 10.8 .79
BHI (% s−1) 1.9 ± 0.5 1.8 ± 0.4 −0.1 .12 0.7 14.0 .70
MAP baseline (mm Hg) 82 ± 14 79 ± 12 −1.5 .64 0.7 13.1 .49
MAP Δ during BH (mm Hg) 10 ± 7 9 ± 8 0.5 .77 1.1 150.7 .46
MAP peak (mm Hg) 93 ± 16 91 ± 17 −1.9 .58 0.9 14.8 .57
CVCi (cm/s mm Hg) 1.08 ± 0.2 1.06 ± 0.2 −0.1 .65 0.3 30.6 .72
Δ End-Tidal CO2 5 ± 3 4 ± 3 0.33 .42 0.4 30.2 .86
Stimulus index (CO2/O2) break point 0.4 ± 0.1 0.4 ± 0.1 0.00 .56 0.3 3.9 .91
Note: Data presented as mean ± SD. Bold indicates significant mean difference between assessments 1 and 2.
Abbreviations: BH, breath-hold; BHI, breath-hold index; CO2, carbon dioxide; CV, coefficient of variation; CVR, cerebrovascular reactivity; MAP, mean
arterial pressure; MCAVmean, mean middle cerebral artery velocity; O2, oxygen.
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3.2 | Within-day reliability
The within-day reliability for parameters of interest is presented in
Table 2. Between assessments 1 and 2, a significant decline in base-
line (ηp
2 = 0.24), peak (ηp
2 = 0.24), and recovery (ηp
2 = 0.22) MCAVmean
was observed. No significant mean differences were apparent
between assessments 1 and 2 for all other outcomes (ηp
2 ≤ 0.12). Sig-
nificant correlations were observed between assessments 1 and 2 for
all outcomes (.46 < r < .91, P < .01).
3.3 | Between-day reliability
The between-day reliability for parameters of interest is presented in
Table 3. Significant mean differences were observed for BHI with a
decline between assessments 1 and 2 (ηp
2 = 0.34). No significant
mean differences were apparent between assessments 1 and 2 for all
other outcomes (ηp
2 ≤ 0.14). Significant correlations were observed
between assessments 1 and 2 for all variables (.46 < r < .83; P < .01),
except CVCi, and PETO2.
4 | DISCUSSION
The main findings of this study were twofold. Within-test analyses
demonstrated that that there were no significant differences across
the three breath-holds performed in the protocol, deeming it appro-
priate to average the CVR from the three breath-hold attempts.
Within- and between-day analyses for CVR using the percentage
increase in MCAvmean following a breath-hold stimulus, yielded similar
and encouraging levels of reliability (typical error expressed as a CV%
of 10.8% and 15.3%, respectively).
4.1 | Within-test
The commonly used BHI outcome yielded a typical error expressed as
a CV% of 16.2% for within-test reliability, in line with previously
reported data (11.4%) in healthy adults.27 Nevertheless, there are con-
cerns with the application of the BHI28 as the relationship between
breath-hold length and the PaCO2 stimulus remains unclear, with
these data often not reported.29,30 The BHI method was first
employed to account for differences in breath-hold length and its pos-
sible influence on CVR, as it is thought to reflect the PaCO2 stimu-
lus,12 considered to have merit in elderly patients who could not hold
their breath for longer than 15 seconds.7 The present study found
that breath-hold length was not significantly associated with the
increase in MCAvmean (r > .31, P > .08), nor the magnitude of the
PETCO2 stimulus index (r > .04, P > .44), and therefore the normaliza-
tion of CVR to breath-hold length holds limited statistical support, at
least within a sample of healthy adolescents. This is in line with adult
data demonstrating breath-hold length is not strongly correlated with
changes in PaCO2.
31 Collectively, these data indicate that it is not
appropriate to normalize the MCAvmean response to breath-hold
length in healthy adolescents. One consideration that may have
biased this analysis is that the present study used a 30-second maxi-
mal breath-hold length; therefore, it is impossible to determine if the
BHI has merit with larger variations in breath-hold length. However,
the present study indicates that when comparing between partici-
pants using a 30-second stimulus cut-off, breath-hold length did not
alter the CVR.
There is a lack of consistency in the determination of CVR from a
breath-hold stimulus, and it is evident that protocol standardization is
needed, with no consensus for protocol and analysis methods of CVR.
Some studies determine peak MCAvmean in the 4 seconds following
the breath-hold,12 while others analyze the peak during the breath-
TABLE 3 Between-day reliability
Variable Assessment 1 Assessment 2
Change




error as CV (%) r
Baseline MCAvmean (cm/s) 84.1 ± 14.7 87.1 ± 12.0 3.0 .11 0.4 6.6 .83
Peak MCAvmean (cm/s) 125.9 ± 22.4 127.0 ± 17.5 1.1 .73 0.5 7.6 .78
Recovery MCAvmean (cm/s) 78.2 ± 14.8 80.8 ± 11.6 2.7 .16 5.98 7.5 .82
BH length (s) 24.2 ± 5.0 25.5 ± 4.6 1.3 .11 0.5 11.5 .74
CVR (%) 49.4 ± 12.0 46.3 ± 12.0 −3.1 .17 0.7 15.3 .64
BHI (% s−1) 2.1 ± 0.5 1.9 ± 0.4 −0.2 .005 0.6 12.5 .74
MAP baseline (mm Hg) 82 ± 14 85 ± 7 3.4 .30 1.0 15.2 .11
MAP Δ during BH (mm Hg) 9 ± 9 8 ± 7 −1.5 .45 6.2 100.2 .48
MAP peak (mm Hg) 96 ± 4 98 ± 10 1.7 .59 1.12 12.9 .46
CVCi (cm/s mm Hg) 1.0 ± 0.2 1.0 ± 0.2 0.0 .72 0.2 16 .39
Δ End-Tidal CO2 4 ± 3 4 ± 3 0.3 .52 0.5 25.9 .76
Stimulus index (CO2/O2) break point 0.4 ± 0.0 0.4 ± 0.0 0.02 .84 0.03 8.1 .60
Note: Bold indicates significant mean difference between assessments 1 and 2. Data presented as mean ± SD.
Abbreviations: BH, breath-hold; BHI, breath-hold index; CO2, carbon dioxide; CV, coefficient of variation; CVR, cerebrovascular reactivity; MAP, mean
arterial pressure; MCAVmean, mean middle cerebral artery velocity; O2, oxygen.
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hold.27 In addition, some studies take the increase in MCAVmean
“immediately following” the breath-hold, though when this occurs is
not stated.7 In the present study, the time taken to peak MCAvmean
following the breath-hold was variable between (4.1 ± 1.8 seconds)
and within (CV = 65.3%) individuals. This may be due to the contin-
gency of the time to peak outcome on the heart rate of the partici-
pant, as MCAvmean is determined on a beat-to-beat basis. This
indicates that using a predefined point of 4 seconds following the
breath-hold, such as in previous studies12 is unlikely to always capture
the peak increase in MCAvmean. In the present study, peak MCAvmean
always occurred in the 10 seconds following the breath-hold, in line
with previous literature.32 This informed subsequent analyses for
within- and between-day outcomes. Similarly to the widely used
approach for interpretation of peripheral endothelial function using
flow mediated dilation,33 it is recommended that researchers use peak
MCAvmean, whenever it occurs following the breath-hold.
It has not been made clear in previous studies whether breath-
hold data are reported as an average across several attempts, or
whether the highest or lowest attempts are removed. In addition, it is
not clear or consistent how many breath-holds are performed, with
some studies reporting six,18 three,34 or two,12 while others fail to
report this.27 From the three breath-hold protocol used in the current
study, baseline and peak MCAvmean systematically declined from
breath-hold one, with no difference between breath-holds two and
three. However, there were no significant differences across breath-
holds for CVR, with breath-hold one to three being strongly correlated
(r = .77) with a within participant CV of 15.2%. It therefore seems
appropriate to take an average of the three breath-holds for analysis,
and also suggests that a single breath-hold may be sufficient for calcu-
lation of CVR if required for a time sensitive protocol.
4.2 | Within- and between-day reliability
Evidence of within- and between-day reliability of breath-hold
induced CVR protocols is essential when conducting interventional
and observational studies. In the present study, within-day data dem-
onstrated a systematic decline in baseline and peak MCAvmean after
60 minutes from assessments 1 to 2. Previous literature has reported
diurnal variation in MCAvmean due to variations in MAP.
35 However,
in the present study, measures of CVCi demonstrated no differences
between assessments both within- and between-days. This suggests
that, although there was a high individual variation in MAP, when
baseline MAP was accounted for, the CVR response was seemingly
not influenced by this variation in MAP. This lends supports to the
use of a breath-hold protocol as a measure of CO2-induced vessel
reactivity. The 1-hour within-day variation of baseline MCAvmean
highlights the time sensitivity of this measure and the importance of
conducting measures at the same time of day to minimize variation.
Despite this, CVR was not significantly different within-day and
evidenced a CV of 10.8%. This indicates that the responsiveness of
the vessel is not altered through the day despite different baseline
MCAvmean. The reliability of CVR may be considered as acceptable
when compared to the within-day CV following CO2 breathing tests
in adults ranging from 4.8% to 40.6%.36
In the present study, between-day CVR assessments were corre-
lated (r = .64) and elicited a CV of 15.3% (r = .64, P = .002). This is
consistent with CVR data from CO2 breathing in adults, with a
between-day intraclass correlation coefficient of 0.73.17 The magni-
tude of the relative change in MCAvmean following the breath-hold
stimulus (34%-62%) is in line with previous reports of normal variation
in a pediatric population of between 40% and 69%.7
The reported variability in CVR between and within-days in the
current study could be attributed to a number of potential sources of
error in the breath-hold protocol. It is important that the breath-hold
is completed following a normal inspiration, to avoid substantial alter-
ations in PaCO2 concentrations,
7 and avoid alterations in MAP during
and after a Valsalva maneuver, which may result in misinterpretation
of CVR.12 However, in this study and previous literature,15 it is evi-
dent that this protocol is well tolerated and appropriately performed
in most adolescents. In the present study, MAP baseline and peak
were reliable within a participant, both within (CV: baseline = 13.1%
and peak = 14.8%) and between-day (CV: baseline = 15.2% and
peak = 12.9%). However, the change in MAP during the breath-hold
was highly variable with both within-day (CV = 150.7%) and between-
day (CV = 100.2%). Although this variation is large, this is summative
of the variation of MAP at both baseline and peak, and when
expressed as a percentage this variability becomes amplified. Despite
this seemingly large variation, there were no resultant changes in
CVR, supporting these changes in MAP as being acceptable ranges
and not having a substantial influence on the subsequent MCAvmean
response. Measurement of both MAP and PETCO2 are of importance
to ensure that any changes in CVR are attributable to changes in
responsiveness in the blood vessel, and not breath-hold execution. In
the current study, PETCO2 at break point was reliable within a partici-
pant, both within-day (CV = 2.9%) and between-day (CV = 3.2%), and
therefore any influence on the variability on outcomes of CVR is
unlikely to be from variability in PETCO2 following breath-hold
execution.
4.3 | Considerations
In the present study, there were no sex differences between out-
comes of interest. However, effect sizes demonstrated a moderate
effect of sex on baseline MCAvmean, with girls displaying a higher
baseline MCAvmean on average than boys. This is in line with arterial
spin labeling data on the impact of puberty on evolution of cerebral
perfusion during adolescence.37 This highlights the need for future
research to continue to explore the influence of sex on markers of
cerebrovascular health. It should be noted that although the breath-
hold is a commonly used noninvasive technique for accessing CVR to
a CO2 stimulus, the PaCO2 levels cannot be standardized and are con-
stantly changing, with the time course of PaCO2 changes and peak
responses unknown. Furthermore, the breath-hold protocol is accom-
panied by hypoxia and blood pressure changes which may confound
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the stimulus effect.38 Despite this, it is a commonly used technique,
particularly in pediatric studies,7,8,39 and therefore knowledge on the
reliability and analysis of this outcome is imperative. In the present
study, a valsalva criteria cut off of a 15 mm Hg increase in blood pres-
sure following the breath-hold. Although there is no study which
directly informs this, the present study introduced this standardization
upon laboratory observations, and data highlighting that a valsalva
maneuver increases in MCAv with a 12 mm Hg increase in MAP.40
5 | CONCLUSIONS
Analyses revealed that breath-hold length and CVR were unrelated,
and provided no statistical justification for the commonly reported
BHI, at least in healthy youth. Within-test analyses demonstrated that
CVR was reproducible within a protocol, indicating that it was appro-
priate to take an average of the three breath-holds. Using these
methods, this study addressed the within- and between-day reliability
of a single protocol to noninvasively measure CVR of the MCA. The
present study demonstrated that the breath-hold protocol was a reli-
able method of assessing CVR in adolescents. Importantly, this sup-
ports its use in future studies investigating changes in CVR that
utilizes measures between and within visits. Future analyses, however,
need to be conducted to establish whether CVR assessed by this
method is valid, and correlates with direct measures of CO2 breathing
techniques. Furthermore, associations with clinical outcomes to sup-
port this as a valuable predictor of future health outcomes warrants
investigation.
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